65H Stock Overview
HTG Molecular Diagnostics, Inc. a life sciences company, focuses on the precision medicine.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
HTG Molecular Diagnostics, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.64 |
52 Week High | US$24.72 |
52 Week Low | US$0.64 |
Beta | 1.05 |
1 Month Change | 0% |
3 Month Change | -91.91% |
1 Year Change | -96.44% |
3 Year Change | -98.82% |
5 Year Change | -99.90% |
Change since IPO | -99.94% |
Recent News & Updates
Recent updates
Shareholder Returns
65H | DE Healthcare Services | DE Market | |
---|---|---|---|
7D | 0% | 7.0% | 2.5% |
1Y | -96.4% | -18.1% | 7.0% |
Return vs Industry: 65H underperformed the German Healthcare Services industry which returned -10.2% over the past year.
Return vs Market: 65H underperformed the German Market which returned 5.9% over the past year.
Price Volatility
65H volatility | |
---|---|
65H Average Weekly Movement | n/a |
Healthcare Services Industry Average Movement | 3.6% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.1% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 65H's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 65H's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1997 | 88 | John Lubniewski | https://www.htgmolecular.com |
HTG Molecular Diagnostics, Inc. a life sciences company, focuses on the precision medicine. The company offers instruments; consumables comprising assay kits; and software that automate sample processing and profiles various molecular targets. Its marketed molecular profiling panels include HTG Transcriptome Panel; HTG EdgeSeq precision immuno-oncology panel; HTG EdgeSeq miRNA whole-transcriptome assay; HTG EdgeSeq DLBCL cell of origin assay EU; HTG EdgeSeq DLBCL cell of origin assay; HTG EdgeSeq Oncology Biomarker Panel; HTG EdgeSeq ALKPlus assay EU; HTG EdgeSeq Pan B-Cell Lymphoma Panel; HTG immune response panel; and HTG mouse mRNA tumor response panel.
HTG Molecular Diagnostics, Inc. Fundamentals Summary
65H fundamental statistics | |
---|---|
Market cap | €5.85m |
Earnings (TTM) | -€20.72m |
Revenue (TTM) | €6.38m |
0.9x
P/S Ratio-0.3x
P/E RatioIs 65H overvalued?
See Fair Value and valuation analysisEarnings & Revenue
65H income statement (TTM) | |
---|---|
Revenue | US$6.80m |
Cost of Revenue | US$11.72m |
Gross Profit | -US$4.92m |
Other Expenses | US$17.18m |
Earnings | -US$22.09m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
Earnings per share (EPS) | -9.99 |
Gross Margin | -72.24% |
Net Profit Margin | -324.71% |
Debt/Equity Ratio | 750.2% |
How did 65H perform over the long term?
See historical performance and comparison